Organon & Co. reported a total revenue of $6.2 billion for the fiscal year ending December 31, 2025, reflecting a 3% decrease from $6.4 billion in 2024. The decline was attributed to lower sales in key product lines, particularly Atozet, Singulair, and Dulera, which faced increased competition and pricing pressures. The company's gross profit also fell by 11% to $3.3 billion, primarily due to rising costs associated with optimizing its manufacturing and supply network. The net income for 2025 was $187 million, a significant drop from $864 million in the previous year, leading to diluted earnings per share of $0.72 compared to $3.33 in 2024.
In terms of operational changes, Organon divested its Jada System to Laborie Medical Technologies for up to $465 million in January 2026, a strategic move aimed at strengthening its balance sheet and enhancing future growth opportunities. The company also acquired the U.S. regulatory and commercial rights for Tofidence, a biosimilar to Actemra, from Biogen, which is expected to contribute positively to its revenue stream. Additionally, the company has been focusing on reducing its debt, which stood at approximately $8.6 billion as of December 31, 2025, by implementing cost-cutting measures and restructuring initiatives that resulted in a 6% reduction in headcount.
Organon’s product portfolio includes over 70 products, with a significant focus on women's health, which generated approximately $1.8 billion in revenue, accounting for 28% of total sales. The company reported that 74% of its revenues were generated outside the United States, highlighting its global reach. However, the company faced challenges in maintaining market exclusivity for key products like Nexplanon, which is set to lose exclusivity in various markets starting in 2026. The company is actively pursuing opportunities to expand its biosimilars portfolio, which has shown promising growth, particularly with Hadlima, a biosimilar to Humira, which saw a 60% increase in sales.
Looking ahead, Organon has expressed a commitment to enhancing its operational efficiencies and addressing the material weaknesses identified in its internal controls over financial reporting. The company is in the process of implementing a comprehensive remediation plan following an internal investigation into its sales practices. The leadership changes, including the appointment of Joseph Morrissey as Interim CEO, are part of the company's strategy to improve governance and compliance. Organon anticipates that these efforts, along with its focus on product innovation and market expansion, will position the company for future growth despite the ongoing challenges in the pharmaceutical landscape.
About Organon & Co.
Organon & Co. is a global healthcare company specializing in women’s health, biosimilars, and established brands. It develops and markets prescription therapies and medical devices across therapeutic areas like contraception, fertility, oncology, immunology, and cardiovascular health. Serving patients worldwide, it leverages a diversified product portfolio, manufacturing capabilities, and strategic collaborations to deliver innovative, cost-effective solutions in competitive markets.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.